Current price 18 cents. Cash since 31/12/02: $7.7 mill. Shares: 193 mill and 25 mil. options at 25 cents on 23/10/2007.
Overview. "Enhancing Drug Performance and Delivery: EIF uses Supercritical Fluid (SCF) technologies to re-engineer pharmaceuticals and proteins to improve their bioavailability and delivery.
By applying its expertise in the four SCF technologies - alone or in combination - Eiffel has the capacity to deliver a customized re-engineering solution to enhance the performance and drug delivery of drug formulations with wide-ranging physicochemical properties".
"Eiffel can: improve the performance, bioavailability and absorption of approved drugs
deliver drugs in a more patient-friendly way, such as by replacing an injection with a tablet or puffer
extend the patent life of originator brands
1. The four Technologies:
Eiffel has research expertise in the four known SCF processes:
RESS - Rapid Expansion of Supercritical Solution
ASES - Aerosol Solvent Extraction Systems
GAS - Gas Anti-Solvent Systems
PGSS - Particles from Gas Saturated Solution
This important web site refers to the re-engineering solutions available:
In addition to Eiffel's seven international and provisional patent applications, the company was granted in 2000 a world-wide exclusive licence for SCF technology platforms from the Universities of NSW (Unisearch) and Sydney.
4. Research Strategy: http://www.eiffeltechnologies.com.au/html/commerce_res_strat.asp
